Cabotegravir with rilpivirine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection

Published on 13 Sep 2024
Last Updated on 13 Sep 2024

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended cabotegravir with rilpivirine for inclusion on the MOH List of Subsidised Drugs for treating Human Immunodeficiency Virus type 1 (HIV-1) infection. The decision was based on the unfavourable cost-effectiveness of cabotegravir with rilpivirine at the price proposed by the company compared with subsidised oral antiretroviral therapies.

Cabotegravir with rilpivirine for treating Human Immunodeficiency Virus type 1 infection (Published 13 Sep 2024) [PDF, 138 KB]

PES Cabotegravir with rilpivirine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection (Published 13 Sep 2024) [PDF, 108 KB]